Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer

Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer

This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.

Inclusion Criteria:

• Be at least 19 years of age.
• Diagnosis of colon cancer
• Scheduled to undergo surgical resection

Exclusion Criteria:

• Inability to provide informed consent
• Pregnancy
• Inability to lie still for the imaging study
• Weight over 350 lbs., due to the scanner bore size
• Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)
• Inability to receive Omnipaque (iohexol) iodinated contrast
• Inability to receive glucagon
• Inability to receive Eovist (gadoxetate disodium) gadolinium based contrast agent
• Allergy to contrast imaging agents
• Finding or suspicion of distant metastases on CT